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ABSTRACT
Combined pituitary hormone deficiency (CPHD) has an incidence
of approximately 1 in 8000 births. Although the proportion of familial
CPHD cases is unknown, about 10% have an affected first degree
relative. We have recently reported three mutations in the PROP1
gene that cause CPHD in human subjects. We report here the fre-
quency of one of these mutations, a 301–302delAG deletion in exon 2
of PROP1, in 10 independently ascertained CPHD kindreds and 21
sporadic cases of CPHD from 8 different countries. Our results show
that 55% (11 of 20) of PROP1 alleles have the 301–302delAG deletion
in familial CPHD cases. Interestingly, although only 12% (5 of 42) of
the PROP1 alleles of our 21 sporadic cases were 301–302delAG, the
frequency of this allele (in 20 of 21 of the sporadic subjects given TRH
stimulation tests) was 50% (3 of 6) and 0% (0 of 34) in the CPHD cases
with pituitary and hypothalamic defects, respectively. Using whole
genome radiation hybrid analysis, we localized the PROP1 gene to the
distal end of chromosome 5q and identified a tightly linked polymor-
phic marker, D5S408, which can be used in segregation studies. Anal-
ysis of this marker in affected subjects with the 301–302delAG de-
letion suggests that rather than being inherited from a common
founder, the 301–302delAG may be a recurring mutation. (J Clin
Endocrinol Metab 83: 3346–3349, 1998)
CONGENITAL defects of the pituitary include autoso-mal recessive, autosomal dominant, and X-linked
forms which have combined deficiencies of anterior pituitary
tropic hormones (CPHD). In CPHD, deficiencies of ACTH,
gonadotropin, GH, PRL, and/or TSH occur, causing growth
failure and altered sexual development, including small gen-
italia in males, delayed or incomplete secondary sexual de-
velopment with infertility, and shortened life expectancy
(1–3).
There are now two genes known to cause CPHD in hu-
mans: PIT1 and Prophet of PIT1 (PROP1). Although the
number of families with reported PIT1 defects is small, a
recent report suggests that a significant proportion of familial
CPHD cases may have PROP1 defects (4). Furthermore, three
of four of the CPHD families reported had a 2-bp deletion
(301–302delAG) in exon 2 of PROP1, suggesting that the
301–302delAG mutation may be a major cause of CPHD.
To determine the frequency of the 301–302delAG deletion
in CPHD subjects we screened all of our familial (n 5 10) and
sporadic (n 5 21) CPHD cases. Included in the familial stud-
ies are three kindreds (see 6, 7, and 9 in Fig. 1), who have been
reported previously (4). We also identified a polymorphic
marker genetically linked to the PROP1 gene and used it to
determine whether the 301–302delAG deletions were inher-
ited from a common founder or arose from recurring
mutations.
Subjects and Methods
Subjects
We studied DNAs from 10 nonrelated kindreds with multiple indi-
viduals with CPHD and 21 sporadic CPHD cases from 8 different coun-
tries. Affected subjects were diagnosed with CPHD by their own en-
docrinologists. Diagnosis was based on clinical and biochemical studies
that documented deficiencies of multiple pituitary tropic hormones,
including GH. Three of the kindreds were of Russian ancestry, and the
7 remaining kindreds studied were of Brazilian, Turkish, Portuguese,
Austrian, Venezuelan, Swiss, and European ancestry (see Fig. 1) (4, 5).
We also studied 20 sporadic CPHD cases from Brazil and 1 sporadic case
from Russia.
In 20 of 21 sporadic subjects, TRH stimulation tests were performed
using 200 mg TRH, iv. Blood samples for TSH levels were drawn at 0,
15, 30, 45, 60, 90, and 120 min after TRH injection (see Table 1). TSH levels
were determined by immunoenzymatic assay (Baxter, Stone Mountain,
GA). PRL levels were measured by immunofluorometric assay before
(basal) and after (peak) TRH stimulation (DELFIA, Wallac, Finland).
PCR amplification of genomic DNA, restriction
endonuclease detection, and DNA sequencing of mutation
Exon 2 of the PROP1 genes of each affected subject were PCR am-
plified. Genomic DNA (400 ng) was added to a 50-mL reaction mixture
of 10 mmol/L Tris-HCl (pH 8.3), 1.5 mmol/L MgCl2, 25 mmol/L KCl,
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200 mmol/L of each deoxy (d)-NTP, 15 pmol of each primer, and 1.75
U AmpliTaq Gold DNA polymerase (Perkin-Elmer, Branchburg, NJ).
The forward and reverse primers were 59-GACAGGCACATGTG-
GTCCA-39 and 59-AGGCCTGTGTCTGGTGACCA-39, respectively. The
PCR reaction mixture was denatured for 10 min at 94 C and cycled 34
times (94 C for 30 s, 55 C for 30 s, and 72 C for 30 s), followed by a 10-min
extension at 72 C. The resulting PROP1 PCR products (416 or 414 bp)
were cleaned by filtration with a Microcon-50 microconcentrator (Ami-
con Corp., Danvers, MA) and used as templates for restriction endo-
nuclease digestion and direct sequencing. Aliquots of the PROP1 PCR
products were digested with BcgI at 37 C for 4 h, and the fragments were
separated on a 3.5% Metaphor agarose (FMC BioProducts, Rockland,
ME) gel and visualized by ethidium bromide staining (Fig. 2). Products
with altered BcgI restriction patterns were then sequenced by the
dideoxy method using the Thermo Sequenase cycle sequencing system
(Amersham Life Science, Cleveland, OH; Fig. 3).
Radiation hybrid (RH) mapping
RH mapping was performed using the Genebridge 4 (GB4) and the
Stanford (G3) whole genome RH panels (Research Genetics, Huntsville,
AL), which consist of 93 and 83 genomic DNAs from human-on-hamster
somatic cell lines, respectively (6, 7). Genomic DNAs (25 ng) were added
to 10-mL PCR reaction mixtures of 10 mmol/L Tris-HCl (pH 8.3), 1.5
mmol/L MgCl2, 25 mmol/L KCl, 200 mmol/L of each dNTP, 3 pmol of
each primer (see primer sequences above), and 0.35 U AmpliTaq Gold
DNA polymerase (Perkin-Elmer). The PCR reactions were then cycled
as described in the above section, and the 416-bp products were sepa-
rated on a 2% agarose gel and visualized by ethidium bromide staining.
The GB4 and G3 RH results were analyzed by the software programs on
the Whitehead Institute/MIT Center for Genome Research (http://
www-genome.wi.mit.edu/) and the Stanford Human Genome Center
(http://shgc-www.stanford.edu/) web pages, respectively.
Microsatellite studies
Genomic DNAs were genotyped for a dinucleotide repeat polymor-
phism (D5S408) linked to the PROP1 gene. Genomic DNA (200 ng) was
added to a 50-mL reaction mixture of 10 mmol/L Tris-HCl (pH 8.3), 1.5
mmol/L MgCl2, 25 mmol/L KCl, 200 mmol/L/L of each dNTP, 1.5 pmol
of 59-end labeled forward oligonucleotide primer, 1.5 pmol reverse oli-
gonucleotide primer, and 2.5 U Taq polymerase (Life Technologies,
Gaithersburg, MD). The forward and reverse primers were 59-ACAACT-
TCCAACCCTGAGAT-39 and 59-ACTGTGCCTAGCCTTCATTT-39, re-
spectively. The PCR reaction mixture was denatured for 3 min at 94 C
and cycled 32 times (94 C for 30 s, 55 C for 30 s, and 72 C for 30 s), followed
by a 10-min extension at 72 C. The products were separated on a 6%
denaturing polyacrylamide gel and visualized by autoradiography
(Fig. 4).
Results
Restriction endonuclease detection of the PROP1
301–302delAG mutation
The exon 2 301–302delAG deletion described by Wu et al.
creates a BcgI restriction endonuclease site that was used to
screen the PCR products, derived from exon 2 of the PROP1
genes, of a series of CPHD subjects for the 2-bp deletion.
Digestion of the 414-bp PROP1 PCR products from affected
subjects with the 301–302delAG allele generated 3 fragments
FIG. 1. Schematic drawings of CPHD
kindreds from Russia (1–3), Portugal
(4), Austria (5), Europe (6), Brazil (7),
Venezuela (8), Switzerland (9), and
Turkey (10). Affected males and fe-
males are indicated by solid squares
and circles, respectively. The 301–
302delAG (D) vs. non301–302delAG
(nonD) genotypes (see Figs. 2 and 3) and
D5S408 A-E alleles (see Fig. 4) are
shown below individual symbols.
TABLE 1. TRH stimulation test results on sporadic CPHD subjects with PROP1 301-302delAG
Subject no. D/N
TSH (mU/L)a after TRH PRL (ng/mL)b
0 min 15 min 30 min 45 min 60 min 90 min 120 min Basal Peak
1 D /D 1.5 3.3 4.3 4.1 3.6 2.8 ND 1.4 5.6
2 D/N 1.4 6.4 5.1 4.4 3.8 2.3 2.0 0.82 2.7
3 N/N 0.2 0.3 ND 0.4 0.2 0.2 0.2 1.0 3.2
4 D /D ND ND ND ND ND ND ND ND ND
a Normal basal and peak TSH responses are 1.8 6 0.8 and 11.1 6 0.8 and 11.1 6 5.5 mU/L.
b Normal basal and peak PRL responses are 12 6 11.2 ng/mL (mean 6 SD; range, 3.5–39.3 ng/mL) and 58.7 6 27 ng/mL (mean 6 1 SD; range,
20–116 ng/mL), respectively.
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of 247, 133, and 34 bp (see Fig. 2). The presence of the 414-bp
fragment as well as the 247- and 133-bp fragments derived
from DNAs of some CPHD samples indicates that they are
heterozygous for 301–302delAG. Of the 10 familial cases
studied, 5 were homozygous (families 1, 2, 4, 5, and 6) and
1 was heterozygous (family 3) for 301–302delAG (see Fig. 1).
Of the 21 sporadic cases, 2 were homozygous and 1 was
heterozygous for 301–302delAG. The results of the BcgI re-
striction endonuclease digest were confirmed by DNA se-
quencing of the PROP1 PCR products (see Fig. 3). Analysis
of PROP1 PCR products from 69 nonrelated controls (CEPH
panel of DNAs) did not detect any 301–302delAG alleles
(data not shown).
RH mapping of PROP1
The GB4 and G3 human whole genome RH panels were
analyzed to determine the chromosomal location of the
PROP1 gene and to identify nearby polymorphic markers
that could be used in segregation studies of CPHD families
(6, 7). The results of our analysis placed PROP1 on the distal
end of chromosome 5q, 9.76 cR (;2.6 Mb) below WI-6737 and
6.62 cR (;200 kb) from SHGC-4669 for the GB4 and G3
panels, respectively. Using the Whitehead and Stanford RH
maps, we identified D5S408 as the nearest polymorphic
marker to PROP1, and we studied its transmission pattern in
3 nonrelated CPHD kindreds with known PROP1 gene de-
fects. The results (0 recombinants of 18 meioses tested) were
consistent with cosegregation of the D5S408 marker and the
PROP1 gene in all 3 families.
Genotyping of CPHD subjects for the 301–302delAG
PROP1 allele
To determine whether 301–302delAG alleles from differ-
ent CPHD subjects were derived from a single common
founder mutation or arose through recurring mutations, we
determined the D5S408 genotype of six nonrelated CPHD
subjects (familial cases 1, 2, 4, 5, and 6 and one sporadic case;
see Fig. 4). Each subject was known to be homozygous for the
301–302delAG PROP1 allele. Direct comparison of the mic-
rosatellite products from one CPHD subject from each of the
five kindreds showed that the 301–302delAG PROP1 alleles
of each subject were adjacent to different D5S408 alleles.
Discussion
The PROP1 301–302delAG allele was first reported in 3 of
4 familial CPHD subjects studied (2 homozygotes and 1
FIG. 2. Electrophoretic analysis of PCR amplification products of
subjects (kindred 4) after digestion with BcgI. The asterisk shows the
size of an artifactual PCR product that was seen in most products
before and after digestion with BcgI. MW, Mol wt standard; Ctrl,
unaffected control.
FIG. 3. DNA sequence analysis of
the PCR products containing segments
of the PROP1 alleles of a control sub-
ject and CPHD individuals whose re-
striction patterns indicated non-301–
302delAG/non-301–302delAG (control),
301–302delAG/301–302delAG (homozy-
gotes), and 301–302delAG/non301–
302delAG (heterozygotes) PROP1 geno-
types, respectively.
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compound heterozygote), thus 5 of 8 (62%) of the PROP1
alleles studied. This 2-bp deletion leads to a frame shift at
codon 101 that results in a premature termination at codon
109. The predicted translation product is truncated with loss
of the DNA-binding homeo- and C-terminal trans-activation
domains of PROP1. We report here that 6 of 10 probands
from independent kindreds (5 homozygous and 1 heterozy-
gous) and 3 of 21 sporadic CPHD subjects (2 homozygous
and 1 heterozygous) studied have the 301–302delAG PROP1
allele. Thus, our raw data show that 301–302delAG com-
prises approximately 55% (11 of 20) and 12% (5 of 42) of all
PROP1 alleles in consecutive familial and sporadic CPHD
cases studied, respectively.
Upon further clinical examination of our sporadic CPHD
subjects we found that 20 of 21 of our subjects had been given
TRH stimulation tests. Of the subjects studied, 3 of 20 had
deficient peak TSH/PRL responses to TRH compared to local
standards. A low normal or impaired TSH response com-
bined with a low PRL level indicate pituitary lesions,
whereas an exaggerated or delayed peak TSH response in-
dicates hypothalamic dysfunction (8). This further subdi-
vides our sporadic cases into a multiple hypopituitary group
(3 of 20) and a multiple hypothalamic group (17 of 20).
Interestingly, 2 of 3 of the sporadic subjects in the multiple
hypopituitary group were found to have 301–302delAG (1
homozygote and 1 heterozygote), making the frequency of
the 301–302delAG allele 50% (3 of 6) for these subjects. This
is in agreement with normal expression of PROP1 being
required for pituitary development. It is likely that subject 2
and possibly subject 3 have 1 or 2 PROP1 alleles, respectively,
that have defects other than 301–302delAG.
Our finding of different D5S408 alleles adjacent to the
301–302delAG deletions from different CPHD families sug-
gests that these deletions probably arose as independent
recurring mutations rather than being inherited from a single
common founder mutation. Previous studies have shown
that mutagenic errors, such as deletions and insertions, tend
to occur in regions where DNA symmetry may interfere with
the normal process of replication, repair, and recombination
(9). Repeat sequence mutations are thought to be a common
cause of human disease and can best be explained by the
Streisinger slippage-repair model (10, 11). In this model,
DNA slippage occurs when one DNA strand dissociates
from the other and then reanneals in a misaligned configu-
ration. Our findings suggest that the three tandem AG re-
peats (AGAGAG) of exon 2 of PROP1 may constitute a hot
spot for recurring mutations that yield the 301–302delAG
allele through this mechanism.
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FIG. 4. Analysis of D5S408 genotypes (A–E) of 301–302delAG/301–
302delAG homozygotes from countries credited above (also see Fig. 1).
The Brazilian sample (EE) is from a sporadic case, and the remaining
samples are familial.
PROP1 2-bp DELETION AND CPHD 3349
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 20 August 2015. at 08:01 For personal use only. No other uses without permission. . All rights reserved.
